Distinct Cognitive Trajectories According to Amyloid Positivity in Non-Alzheimer Disease Dementias.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI:10.1097/RLU.0000000000005457

Hyemin Jang, Min Young Chun, Jihwan Yun, Jun Pyo Kim, Sung Hoon Kang, Hee Jin Kim, Duk L Na, Eun Hye Lee, Daeun Shin, Hongki Ham, Yuna Gu, Chi-Hun Kim, Sook-Young Woo, Sang Won Seo

{"title":"Distinct Cognitive Trajectories According to Amyloid Positivity in Non-Alzheimer Disease Dementias.","authors":"Hyemin Jang, Min Young Chun, Jihwan Yun, Jun Pyo Kim, Sung Hoon Kang, Hee Jin Kim, Duk L Na, Eun Hye Lee, Daeun Shin, Hongki Ham, Yuna Gu, Chi-Hun Kim, Sook-Young Woo, Sang Won Seo","doi":"10.1097/RLU.0000000000005457","DOIUrl":null,"url":null,"abstract":"Background: The clinical effects of β-amyloid positivity (Aβ+) on copathologies in various dementias remain relatively underexamined. Thus, the present study was conducted to investigate the prevalence and clinical effects of Aβ+ in subcortical vascular cognitive impairment (SVCI) and frontotemporal dementia (FTD).Patients and methods: We enrolled SVCI (n = 583), FTD (n = 152), and cognitively unimpaired (CU) participants (n = 1,249) who underwent Aβ PET scans. The odds of having Aβ+ were subsequently compared among the diagnostic groups (CU, SVCI, and FTD) according to age and apolipoprotein E genotype. Additionally, a linear mixed-effects model was used to investigate the effects of Aβ+ on cognitive trajectories in SVCI and FTD.Results: Compared with CU, the SVCI group had a higher prevalence of Aβ+ in the 75 to 90 years age group (adjusted odds ratio, 1.97; 95% confidence interval, 1.36-2.85; P < 0.001), as well as within the apolipoprotein E ε3/ε3 group (adjusted odds ratio, 1.78; 95% confidence interval, 1.20-2.63; P = 0.001), whereas the FTD group showed no difference in Aβ+ prevalence. Aβ+ was associated with a worse cognitive trajectory in SVCI (adjusted β-coefficient = -0.6424; P < 0.001), but not in FTD.Conclusions: These findings contribute to our understanding of Aβ biomarker traits in various dementias in Korea.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"1073-1078"},"PeriodicalIF":9.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005457","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The clinical effects of β-amyloid positivity (Aβ+) on copathologies in various dementias remain relatively underexamined. Thus, the present study was conducted to investigate the prevalence and clinical effects of Aβ+ in subcortical vascular cognitive impairment (SVCI) and frontotemporal dementia (FTD).

Patients and methods: We enrolled SVCI (n = 583), FTD (n = 152), and cognitively unimpaired (CU) participants (n = 1,249) who underwent Aβ PET scans. The odds of having Aβ+ were subsequently compared among the diagnostic groups (CU, SVCI, and FTD) according to age and apolipoprotein E genotype. Additionally, a linear mixed-effects model was used to investigate the effects of Aβ+ on cognitive trajectories in SVCI and FTD.

Results: Compared with CU, the SVCI group had a higher prevalence of Aβ+ in the 75 to 90 years age group (adjusted odds ratio, 1.97; 95% confidence interval, 1.36-2.85; P < 0.001), as well as within the apolipoprotein E ε3/ε3 group (adjusted odds ratio, 1.78; 95% confidence interval, 1.20-2.63; P = 0.001), whereas the FTD group showed no difference in Aβ+ prevalence. Aβ+ was associated with a worse cognitive trajectory in SVCI (adjusted β-coefficient = -0.6424; P < 0.001), but not in FTD.

Conclusions: These findings contribute to our understanding of Aβ biomarker traits in various dementias in Korea.

查看原文本刊更多论文

非阿尔茨海默病痴呆症患者淀粉样蛋白阳性率不同的认知轨迹

背景：在各种痴呆症中，β淀粉样蛋白阳性（Aβ+）对共病理学的临床影响仍然相对缺乏研究。因此，本研究旨在调查皮层下血管性认知障碍（SVCI）和额颞叶痴呆（FTD）中 Aβ+ 的患病率和临床影响：我们招募了接受Aβ PET扫描的SVCI（583人）、FTD（152人）和认知功能未受损（CU）的参与者（1249人）。随后，根据年龄和载脂蛋白 E 基因型比较了各诊断组（CU、SVCI 和 FTD）中出现 Aβ+ 的几率。此外，还使用线性混合效应模型研究了Aβ+对SVCI和FTD认知轨迹的影响：与CU相比，SVCI组在75至90岁年龄组中的Aβ+患病率更高（调整后的几率比为1.97；95%置信区间为1.36-2.85；P < 0.001），在载脂蛋白E ε3/ε3组中的Aβ+患病率也更高（调整后的几率比为1.78；95%置信区间为1.20-2.63；P = 0.001），而FTD组的Aβ+患病率没有差异。在SVCI中，Aβ+与认知轨迹变差有关（调整后的β系数=-0.6424；P＜0.001），而在FTD中则无关：这些发现有助于我们了解韩国各种痴呆症的Aβ生物标志物特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.